Skip to content
Catalyst

20-hydroxyecdysoneWhat was measured

Measured, with no finding

177 endpoints

Show what was measuredHide what was measured
  • triglycerides

    no effect, p = 0.62

    triglycerides (p = 0.62)

    PMID 18500969 · one of two readings recorded this

  • uric acid

    no effect, p = 0.57

    uric acid (p = 0.57)

    PMID 18500969 · one of two readings recorded this

  • hemoglobin

    no effect, p = 0.74

    hemoglobin (p = 0.74)

    PMID 18500969 · one of two readings recorded this

  • GGT

    no effect, p = 0.86

    GGT (p = 0.86)

    PMID 18500969 · one of two readings recorded this

  • MCH

    no effect, p = 0.2

    MCH (p = 0.20)

    PMID 18500969 · one of two readings recorded this

  • AST

    no effect, p = 0.16

    AST (p = 0.16)

    PMID 18500969 · one of two readings recorded this

  • 1-RM bench press, training effect

    increases, p = 0.0001

    1-RM bench press (pre: 94.94 ± 22.8 to post: 100.84 ± 20.54 kg, p =< 0.0001)

    PMID 18500969 · one of two readings recorded this

  • 1-RM leg press, training effect

    increases, p = 0.0001

    1-RM leg press (311 ± 76 to 341 ± 82 kg, p =< 0.0001)

    PMID 18500969 · one of two readings recorded this

  • ALT

    no effect, p = 0.56

    ALT (p = 0.56)

    PMID 18500969 · one of two readings recorded this

  • basophils change

    modulates, p = 0.04

    basophils (7.5 ± 7.6; 7.6 ± 25.1; 6.57 ± 16.1; 4.4 ± 7.8 k/μL, p = 0.04)

    PMID 18500969 · one of two readings recorded this

  • bench press 1-RM change

    no effect, p = 0.29

    bench press 1-RM (6.2 ± 7; 2.5 ± 5; 7.2 ± 10; 7.7 ± 6 kg, p = 0.29)

    PMID 18500969 · one of two readings recorded this

  • bench press lifting volume change

    modulates, p = 0.008

    Bench press lifting volume was significantly greater in the M group (105 ± 120; 102 ± 200; 124 ± 174; 25 ± 176 kg, p = 0.008)

    PMID 18500969 · one of two readings recorded this

  • BUN, E arm, T1 to T3

    no effect, p = 0.97

    E | 16.2 ± 3.1 | 15 ± 2.7 | 14.7 ± 3.3 | GxT |.970

    PMID 18500969 · one of two readings recorded this

  • CK, E arm, T1 to T3

    no effect, p = 0.091

    E | 172 ± 83 | 228 ± 133 | 159 ± 64 | GxT |.091

    PMID 18500969 · one of two readings recorded this

  • cortisol change

    no effect, p = 0.57

    cortisol (2.68 ± 2.46, 1.11 ± 6.3, 1.93 ± 5.57, 1.66 ± 10.54 μg/dl, p = 0.57)

    PMID 18500969 · one of two readings recorded this

  • cortisol, E arm, T1 to T3

    no effect, p = 0.571

    E | 17.1 ± 4.5 | 15.6 ± 5.3 | 15.1 ± 5.8 | GxT |.571

    PMID 18500969 · one of two readings recorded this

  • creatinine, E arm, T1 to T3

    no effect, p = 0.537

    E | 1.2 ±.13 | 1.1 ±.16 | 1.2 ±.13 | GxT |.537

    PMID 18500969 · one of two readings recorded this

  • DEXA fat free mass change

    no effect, p = 0.4

    mean fat free mass (P 0.94 ± 1.5; M 0.29 ± 1.4; E -0.04 ± 1.3; CSP3 0.64 ± 1.4 kg, p = 0.40)

    PMID 18500969 · one of two readings recorded this

  • DEXA fat free mass, fat mass, 1-RM bench press and leg press, Wingate power, serum cortisol and testosterone; arm E dosed 100 mg/day Polypodium vulgare/Suma root standardized for 30 mg 20-hydroxyecdysone vs dextrose placebo, 8 weeks with resistance training

    no effect, DEXA fat free mass change among P, M, E and CSP3 groups, p = 0.40, p = 0.4

    Not recorded as a finding: the only supporting sentence runs past the quote limit

    However, no statistically significant differences were observed among the P, M, E, and CSP3 groups, respectively, in mean fat free mass (P 0.94 ± 1.5; M 0.29 ± 1.4; E -0.04 ± 1.3; CSP3 0.64 ± 1.4 kg, p = 0.40), fat mass (P0.69 ± 1.1; M 0.32 ± 1.6; E 0.69 ± 1.1; CSP3 -0.36 ± 0.7 kg, p = 0.17), percent body fat (P 0.59 ± 1.7; M 0.08 ± 1.7; E 0.70 ± 1.0; CSP3 -0.46 ± 0.8%, p = 0.18), or total body water (P 0.39 ± 3.3, M 0.16 ± 2.9, E 1.7 ± 2.5, CSP3 0.31 ± 2.4 L, p = 0.61).

    PMID 18500969 · one of two readings recorded this

  • DEXA fat free mass, fat mass and percent body fat, 1-RM bench press and leg press, Wingate power, serum total testosterone and cortisol, over 8 weeks of resistance training; the Results name the arm only as E, and the only Methods sentence defining E (100 mg/day of Polypodium Vulare/Suma root standardized for 30 mg of 20-hydroxyecdysone) is over 40 words of prose because its brackets carry no digits

    no effect, change in fat free mass, E -0.04 +/- 1.3 kg against P 0.94 +/- 1.5 kg among four groups, p = 0.4

    Not recorded as a finding: the only supporting sentence runs past the quote limit

    However, no statistically significant differences were observed among the P, M, E, and CSP3 groups, respectively, in mean fat free mass (P 0.94 ± 1.5; M 0.29 ± 1.4; E -0.04 ± 1.3; CSP3 0.64 ± 1.4 kg, p = 0.40), fat mass (P0.69 ± 1.1; M 0.32 ± 1.6; E 0.69 ± 1.1; CSP3 -0.36 ± 0.7 kg, p = 0.17), percent body fat (P 0.59 ± 1.7; M 0.08 ± 1.7; E 0.70 ± 1.0; CSP3 -0.46 ± 0.8%, p = 0.18), or total body water (P 0.39 ± 3.3, M 0.16 ± 2.9, E 1.7 ± 2.5, CSP3 0.31 ± 2.4 L, p = 0.61).

    PMID 18500969 · one of two readings recorded this

  • DEXA fat free mass, training effect

    increases, p = 0.03

    Training resulted in a statistically significant increase (p = 0.03) in DEXA fat free mass

    PMID 18500969 · one of two readings recorded this

  • dietary carbohydrate intake, E arm, T1 to T3

    no effect, p = 0.491

    E | 4.7 ± 1 | 3.8 ±.83 | 3.9 ± 1.2 | GxT |.491

    PMID 18500969 · one of two readings recorded this

  • dietary fat intake, E arm, T1 to T3

    no effect, p = 0.67

    E | 1.5 ±.8 | 1.2 ±.29 | 1.2 ±.39 | GxT |.670

    PMID 18500969 · one of two readings recorded this

  • dietary protein intake, E arm, T1 to T3

    no effect, p = 0.815

    E | 1.7 ±.34 | 1.7 ±.34 | 1.4 ±.44 | GxT |.815

    PMID 18500969 · one of two readings recorded this

  • dietary total calories, E arm, T1 to T3

    no effect, p = 0.826

    E | 40 ± 12 | 31 ± 6 | 32 ± 7 | GxT |.826

    PMID 18500969 · one of two readings recorded this

  • eosinophils

    no effect, p = 0.28

    eosinophils (p = 0.28)

    PMID 18500969 · one of two readings recorded this

  • fat mass change

    no effect, p = 0.17

    fat mass (P0.69 ± 1.1; M 0.32 ± 1.6; E 0.69 ± 1.1; CSP3 -0.36 ± 0.7 kg, p = 0.17)

    PMID 18500969 · one of two readings recorded this

  • free testosterone change

    no effect, p = 0.25

    free testosterone (4.39 ± 10.4, 5.54 ± 6.85, 1.39 ± 11.84, 1.77 ± 8.62 pg/ml, p = 0.25)

    PMID 18500969 · one of two readings recorded this

  • hematocrit

    no effect, p = 0.61

    hematocrit (p = 0.61)

    PMID 18500969 · one of two readings recorded this

  • LDH, E arm, T1 to T3

    no effect, p = 0.359

    E | 126 ± 23 | 124 ± 12 | 124 ± 14 | GxT |.359

    PMID 18500969 · one of two readings recorded this

  • leg press 1-RM change

    no effect, p = 0.63

    leg press 1-RM (20.6 ± 33; 37.0 ± 39; 38.9 ± 45; 29.3 ± 36 kg, p = 0.63)

    PMID 18500969 · one of two readings recorded this

  • leg press lifting volume change

    modulates, p = 0.04

    leg press lifting volume was lower in the M group (97 6 ± 1,213; -799 ± 1,718; 1,259 ± 1,153; 978 ± 2,328 kg, p = 0.04)

    PMID 18500969 · one of two readings recorded this

  • lymphocytes

    no effect, p = 0.44

    lymphocytes (p = 0.44)

    PMID 18500969 · one of two readings recorded this

  • MCHC

    no effect, p = 0.29

    MCHC (p = 0.29)

    PMID 18500969 · one of two readings recorded this

  • MCV

    no effect, p = 0.68

    MCV (p = 0.68)

    PMID 18500969 · one of two readings recorded this

  • monocytes

    no effect, p = 0.66

    monocytes (p = 0.66)

    PMID 18500969 · one of two readings recorded this

  • neutrophils change

    modulates, p = 0.04

    significant changes were seen in neutrophils (2.05 ± 9.9; 4.4 ± 10.1; 4.3 ± 5.5, 5.8 ± 7.4 k/μL:, p = 0.04)

    PMID 18500969 · one of two readings recorded this

  • percent body fat change

    no effect, p = 0.18

    percent body fat (P 0.59 ± 1.7; M 0.08 ± 1.7; E 0.70 ± 1.0; CSP3 -0.46 ± 0.8%, p = 0.18)

    PMID 18500969 · one of two readings recorded this

  • red blood cell counts

    no effect, p = 0.39

    red blood cell counts (p = 0.39)

    PMID 18500969 · one of two readings recorded this

  • serum protein

    no effect, p = 0.65

    serum protein (p = 0.65)

    PMID 18500969 · one of two readings recorded this

  • total body water change

    no effect, p = 0.61

    total body water (P 0.39 ± 3.3, M 0.16 ± 2.9, E 1.7 ± 2.5, CSP3 0.31 ± 2.4 L, p = 0.61)

    PMID 18500969 · one of two readings recorded this

  • total cholesterol

    no effect, p = 0.48

    total cholesterol (p = 0.48)

    PMID 18500969 · one of two readings recorded this

  • total lifting volume, lower body

    no effect, p = 0.94

    lower body (P 398,976 ± 77,553; M 408,966 ± 113,746; E 448,371 ± 189,738; CSP3 422,163 ± 167,259 kg; p = 0.94)

    PMID 18500969 · one of two readings recorded this

  • total lifting volume, upper body

    no effect, p = 0.83

    total lifting volume during the training period for upper body (P 322,984 ± 106,936; M 304,987 ± 51,955; E 275,744 ± 72,658; CSP3 313,308 ± 112,077 kg; p = 0.83)

    PMID 18500969 · one of two readings recorded this

  • total testosterone change

    no effect, p = 0.67

    total testosterone (0.21 ± 0.83, 0.26 ± 1, 0.02 ± 1.21, 0.10 ± 0.93 ng/ml, p = 0.67)

    PMID 18500969 · one of two readings recorded this

  • total testosterone to cortisol ratio change

    no effect, p = 0.43

    total testosterone to cortisol ratio (0.05 ± 0.09, 0.02 ± 0.16, 0.06 ± 0.17, 0.02 ± 0.16, p = 0.43)

    PMID 18500969 · one of two readings recorded this

  • WBC

    no effect, p = 0.076

    WBC (p = 0.076)

    PMID 18500969 · one of two readings recorded this

  • Wingate mean power change

    no effect, p = 0.55

    Wingate mean power (20 ± 83; -13 ± 88; -18 ± 76; -15 ± 52 W, p = 0.55)

    PMID 18500969 · one of two readings recorded this

  • Wingate peak power change

    no effect, p = 0.82

    Wingate peak power (82 ± 248; 30 ± 139; 28 ± 151; 17 ± 171 W, p = 0.82)

    PMID 18500969 · one of two readings recorded this

  • Wingate total work change

    no effect, p = 0.29

    Wingate total work (582 ± 2,564; -216 ± 2,716; -420 ± 2,291; -528 ± 1,514 J, p = 0.29)

    PMID 18500969 · one of two readings recorded this

  • Elimination of G. lamblia after therapy

    increases

    After therapy, elimination of G. lamblia was observed in 100.0% of the athletes included in the 20-hydroxyecdysone group

    PMID 36617399 · one of two readings recorded this

  • elimination of Giardia lamblia after therapy in athletes with giardiosis, parasitological analysis

    100.0% elimination in the 20-hydroxyecdysone group

    Not recorded as a finding: this platform holds no node for the endpoint

    After therapy, elimination of G. lamblia was observed in 100.0% of the athletes included in the 20-hydroxyecdysone group.

    PMID 36617399 · one of two readings recorded this

  • elimination of Giardia lamblia after therapy, parasitological analysis

    increases, G. lamblia eliminated in 100.0% of athletes in the 20-hydroxyecdysone group

    Not recorded as a finding: this platform holds no node for the endpoint

    After therapy, elimination of G. lamblia was observed in 100.0% of the athletes included in the 20-hydroxyecdysone group.

    PMID 36617399 · one of two readings recorded this

  • G. lamblia resistance to metronidazole

    G. lamblia was resistant to metronidazole in 4.0% of athletes included in the metronidazole group

    PMID 36617399 · one of two readings recorded this

  • 20E plasma Cmax, fed versus fasted

    increases

    20E plasma Cmax and AUCs were slightly higher in fed than in fasted conditions at 700 mg (+24% for Cmax and +20%–22% for AUCs

    PMID 37057316 · one of two readings recorded this

  • aldosterone, change from baseline at D14

    no effect, p = 0.219

    Aldosterone (pg/mL) | 1.767 (−24.00 + 21.60) | 3.375 (−31.30 + 36.40) | 5.486 (n = 7) (−11.70 + 43.10) | −11.200 (−42.80 + 24.10) | 0.219 (ns) | All: 0.736 (ns) 350 bid: 0.871(ns) | 0.01 0.01

    PMID 37057316 · one of two readings recorded this

  • CK-MB, change from baseline at D14

    no effect, p = 0.368

    CK MB (g/L) | −0.192 (−0.36 + 0.10) | −0.130 (−0.66 + 0.35) | −0.310 (n = 7) (−0.92 + 0.15) | −0.428 (−0.95 + 0.14) | 0.368 (ns) | All: 0.027 (s) 350 mg bid: 0.008 (s) | 0.21 0.79 *

    PMID 37057316 · one of two readings recorded this

  • CK-MB dose effect at Day 14, all healthy volunteers

    decreases, p = 0.043

    CK‐MB levels from all healthy volunteers show a dose effect on Day 14 (P = 0.043; Kruskal–Wallis test)

    PMID 37057316 · one of two readings recorded this

  • CRP, change from baseline at D14

    unclear

    CRP (mg/L) | 0.00 (0.0 0.0) | 0.16 (0.0 + 1.3) | 0.00 (n = 7) (0.0 0.0) | −3.11 (−23.6 0.0) | nd | nd | nd

    PMID 37057316 · one of two readings recorded this

  • hsCRP, change from baseline at D14

    unclear

    hsCRP (mg/L) | 0.807 (−0.64 + 3.45) | 0.024 (−1.32 + 1.53) | −0.466 (n = 7) (−3.30 + 0.59) | −0.018 (n = 6) (−0.33 + 0.32) | nd | nd | nd

    PMID 37057316 · one of two readings recorded this

  • HSP72, change from baseline at D14

    unclear

    HSP72 (ng/mL) | −0.1600 (−3.70 0.0000) | 0.18375 (−0.0500 + 1.5200) | 0.06571 (n = 7) (0.0000 + 0.4600) | −0.0940 (−1.2000 + 0.6489) | nd | nd | nd

    PMID 37057316 · one of two readings recorded this

  • IL-6, change from baseline at D14

    no effect

    IL‐6 (pg/mL) | 0.152 (−1.44 + 3.05) | −1.477 (n = 6) (−8.28 + 3.71) | 0.160 (n = 7) (0.00 + 1.12) | 0.4 6 (−2.52 + 3.20) | nd | nd | nd

    PMID 37057316 · one of two readings recorded this

  • myoglobin, change from baseline at D14

    no effect, p = 0.244

    Myoglobin (ng/mL) | −3.70 (−18.3 + 12.7) | −2.71 (−21.5 + 9.1) | −8.46 (n = 7) (−25.1 + 4.6) | −7.43 (−15.3–3.3) | 0.244 (ns) | All: 0.272 (ns) 350 mg bid: 0.012 (s) | 0.06 0.75 *

    PMID 37057316 · one of two readings recorded this

  • myostatin, change from baseline at D14

    increases, p = 0.032

    Myostatin (pg/mL) | −453.5 (−797–29) | 100.3 (−410 + 831) | 146.4 (n = 7) (−574 + 1048) | 253.4 (−590 + 876) | 0.032 (s) | All: 0.954 (ns) 350 mg bid: 0.906 (ns) | 0.0 0.0

    PMID 37057316 · one of two readings recorded this

  • PIIINP, change from baseline at D14

    no effect, p = 0.359

    PIIINP (μg/mL) | −0.13 (−1.95 + 0.65) | 0.230 (−1.52 + 1.11) | 0.247 (n = 7) (−0.91 + 0.93) | 0.614 (+0.10 + 1.34) | 0.359 (ns) | All: 0.944 (ns) 350 bid: 0.484 (ns) | 0.0 0.1

    PMID 37057316 · one of two readings recorded this

  • plasma 20E pharmacokinetics (Cmax, AUC, half-life, accumulation ratio) by LC-MS/MS after single and 14-day oral BIO101; plasma myostatin by ELISA, change from baseline at day 14 against pooled placebo

    increases, small dose-dependent increase in mean myostatin after 14 days of BIO101 against a decrease on placebo, p = 0.032

    Not recorded as a finding: this platform holds no node for the endpoint

    Mean myostatin levels tended to decrease compared with baseline in subjects who received placebo, while a small increase was observed after 14 days of repeated administration of BIO101, in a dose-dependent manner (Kruskal–Wallis test P = 0.032).

    PMID 37057316 · one of two readings recorded this

  • renin, change from baseline at D14

    no effect, p = 0.103

    Renin (pg/mL) | 0.405 (−1.11 + 2.14) | −0.554 (−5.82 + 1.39) | 1.064 (n = 7) (−0.33 + 4.25) | −1.131 (−6.02 + 4.20) | 0.103 (ns) | All: 0.669 (ns) 350 mg bid: 0.584 | 0.01 0.06

    PMID 37057316 · one of two readings recorded this

  • All-cause mortality at day 28, adjusted difference (CMH)

    no effect, n = 233

    adjusted difference: −6.2%, 95% CI: [−14.5%, 2.2%]

    PMID 38545090 · one of two readings recorded this

  • All-cause mortality at day 28, observed proportion

    decreases

    The proportions of subjects with death from any cause at Day 28 (7.9% vs. 14% in the BIO101 vs. placebo arms respectively)

    PMID 38545090 · one of two readings recorded this

  • All negative events by day 28, sensitivity analysis logistic regression

    decreases

    odds ratio (OR) of 0.47 (95% CI: 0.23, 0.95)

    PMID 38545090 · one of two readings recorded this

  • composite of death or respiratory failure requiring mechanical ventilation, ECMO or high-flow oxygen by day 28, first negative event, CMH test (primary endpoint)

    decreases, adjusted difference -11.4% (95% CI -22.4%, -0.4%), p = 0.0426

    Not recorded as a finding: no_outcome_node: no node for a composite of death or respiratory failure; the closest nodes (all-cause mortality, mechanical-ventilation-duration) measure different constructs.

    In the mITT population, using the CMH test with multiple imputation for missing data, the first negative event rate was statistically significantly lower in the BIO101 group than in the placebo group (adjusted difference: −11.4% [95% CI: −22.4%, −0.4%]; p = 0.0426) (Table 2 A).

    PMID 38545090 · one of two readings recorded this

  • Death or respiratory failure at or before day 28, observed proportion

    decreases, n = 233

    The observed proportion of subjects who met the primary outcome of death or respiratory failure at or before day 28, were 13.5% vs. 24.3%

    PMID 38545090 · one of two readings recorded this

  • Death or respiratory failure by day 28 (first negative event), adjusted difference, CMH with multiple imputation

    decreases, p = 0.0426, n = 233

    adjusted difference: −11.4% [95% CI: −22.4%, −0.4%]; p = 0.0426

    PMID 38545090 · one of two readings recorded this

  • Difference in proportions of deaths at 90 days

    no effect

    The difference in the proportions of deaths at 90 days was 0.093 (95% confidence interval (−0.010, 0.195))

    PMID 38545090 · one of two readings recorded this

  • Discharged from hospital due to improvement at day 28 (key secondary), adjusted difference

    no effect, p = 0.0568, n = 233

    adjusted difference: 11.0% [95% CI: −0.4%, 22.4%], p = 0.0568

    PMID 38545090 · one of two readings recorded this

  • Discharged from hospital due to improvement at day 28, observed proportion

    increases

    The proportion of subjects discharged from hospital due to improvement (positive events) at day 28 was numerically higher in the BIO101 group (80.1%) than in the placebo group (70.9%)

    PMID 38545090 · one of two readings recorded this

  • First negative event: death from any cause

    decreases

    Death from any cause | 1 (0.8) | 3 (2.8)

    PMID 38545090 · one of two readings recorded this

  • First negative event: respiratory failure requiring ECMO

    no effect

    Requiring ECMO | 0 | 0

    PMID 38545090 · one of two readings recorded this

  • First negative event: respiratory failure requiring high flow oxygen

    decreases

    Requiring high flow oxygen d | 2 (1.6) | 8 (7.5)

    PMID 38545090 · one of two readings recorded this

  • First negative event: respiratory failure requiring mechanical ventilation

    decreases

    Requiring mechanical ventilation | 14 (11.1) | 15 (14.0)

    PMID 38545090 · one of two readings recorded this

  • First negative event: respiratory failure

    decreases

    Respiratory failure | 16 (12.7) | 23 (21.5)

    PMID 38545090 · one of two readings recorded this

  • hospital discharge due to improvement by day 28 (key secondary endpoint)

    no effect, 80.1% vs 70.9%, adjusted difference 11.0% (95% CI -0.4%, 22.4%)

    Not recorded as a finding: no_outcome_node: no node for proportion discharged following recovery.

    The proportion of subjects discharged from hospital due to improvement (positive events) at day 28 was numerically higher in the BIO101 group (80.1%) than in the placebo group (70.9%) although this difference did not reach statistical significance (adjusted difference: 11.0% [95% CI: −0.4%, 22.4%], p = 0.0568) (Table 2 A).

    PMID 38545090 · one of two readings recorded this

  • Key secondary endpoint, first positive events (table)

    no effect, p = 0.0586

    Key secondary endpoint b Proportion of patients discharged from hospital due to improvement. (First positive events) | 100.94 (80.1) | 75.91 (70.9) | 9.2 | 11.0 (−0.4, 22.4) | 0.0586

    PMID 38545090 · one of two readings recorded this

  • Mean number of days on treatment

    no effect

    the mean number of days on treatment (BIO101; 8.9 ± 6.13 days vs. Placebo; 7.6 ± 5.36 days)

    PMID 38545090 · one of two readings recorded this

  • Mortality at day 28 death from any cause (table)

    no effect, p = 0.1476

    Mortality at day 28 c Death from any cause | 10 (7.9) | 15 (14.0) | −6.1 | −6.2 (−14.5, 2.2) | 0.1476 (nominal)

    PMID 38545090 · one of two readings recorded this

  • Negative events at day 28, sensitivity analysis Kaplan-Meier proportions difference

    decreases

    difference 10.9%, 95% CI [0.6%, 21.2%]

    PMID 38545090 · one of two readings recorded this

  • Number of subjects with first negative event

    decreases

    Number of subjects with first negative event | 17 (13.5) | 26 (24.3)

    PMID 38545090 · one of two readings recorded this

  • Number of subjects with positive event (discharge)

    unclear

    Number of subjects with positive event e | 93 (73.8) | 71 (66.4)

    PMID 38545090 · one of two readings recorded this

  • Primary endpoint adjusted difference, Brazil

    no effect

    adjusted difference: −12.1%, 95% CI [−25.7%, 1.6%]

    PMID 38545090 · one of two readings recorded this

  • Primary endpoint adjusted difference, France, Belgium and US

    no effect

    adjusted difference −0.14%, 95% CI [−23.3%, 23.0%]

    PMID 38545090 · one of two readings recorded this

  • Primary endpoint adjusted difference, protocol versions 1 to 11

    decreases

    protocol versions 1 to 11 adjusted difference −7.08%, 95% CI [−21.1%, 6.91%]

    PMID 38545090 · one of two readings recorded this

  • Primary endpoint adjusted difference, protocol versions 12-13

    decreases

    protocols 12-13 adjusted difference: −16.2%, 95% CI [−33.6%, 1.22%]

    PMID 38545090 · one of two readings recorded this

  • Primary endpoint first negative events (table), unadjusted and adjusted difference

    decreases, p = 0.0426

    Proportion of patients with death or respiratory failure (First negative events) Primary endpoint d | 19.85 (15.8) | 27.86 (26.0) | −10.3 | −11.4 (−22.4, −0.4) | 0.0426

    PMID 38545090 · one of two readings recorded this

  • proportion of patients with any treatment-emergent adverse event, on-intervention period

    decreases, 73 [57.0%] vs 67 [64.4%]

    Not recorded as a finding: Node supplement-adverse-event-incidence fits, but the sentence gives a direction word and counts with no test or interval, so neither direction is recordable.

    A lower proportion of patients treated with BIO101 experienced any type of TEAEs than placebo subjects (73 [57.0%] vs. 67 [64.4%], respectively).

    PMID 38545090 · one of two readings recorded this

  • Relative risk reduction of death at day 28

    decreases

    BIO101 had a RR reduction of death of 44.3% compared to placebo

    PMID 38545090 · one of two readings recorded this

  • Relative risk reduction of negative events

    decreases

    The RR of having negative events was reduced by 43.8% in the BIO101 arm

    PMID 38545090 · one of two readings recorded this

  • Respiratory failure as first negative event

    decreases

    The most common negative event was respiratory failure and was numerically reduced in the BIO101 group compared to the placebo group (16 subjects, 12.7% vs. 23 subjects, 21.5% respectively)

    PMID 38545090 · one of two readings recorded this

  • Time to death through day 90, hazard ratio (Cox model)

    no effect

    The hazard ratio for time to death through day 90 was 0.554 (95% CI: 0.285, 1.077)

    PMID 38545090 · one of two readings recorded this

  • Time to negative event, Kaplan-Meier hazard ratio

    decreases, p = 0.0223

    Hazard Ratio (95% CI): 0.489 (0.265, 0.904)/Two-sided p-value Log-rank p = 0.0223

    PMID 38545090 · one of two readings recorded this

  • Time to respiratory failure through day 90, hazard ratio (Kaplan Meier)

    no effect

    Kaplan Meier comparison of the time to respiratory failure at Day 90 between the BIO101 and the placebo groups did not reach statistical significance either (HR: 0.530 (95% CI: 0.279, 1.006)

    PMID 38545090 · one of two readings recorded this

  • 4-m walk gait speed from SPPB, LS mean difference to placebo in CFB at Month 6

    no effect, p = 0.8747

    The LS mean (SE) difference to placebo at Month 6 in the GS from the 4‐m walk test from SPPB in the PP population was 0.011 (0.067) and 0.134 (0.074) m/s in the 175‐ and 350‐mg BIO101groups, respectively (p = 0.8747 and p = 0.0745, respectively)

    PMID 40026058 · one of two readings recorded this

  • 4-m walk gait speed from SPPB, LS mean difference to placebo in CFB at Month 6

    no effect, p = 0.0745

    The LS mean (SE) difference to placebo at Month 6 in the GS from the 4‐m walk test from SPPB in the PP population was 0.011 (0.067) and 0.134 (0.074) m/s in the 175‐ and 350‐mg BIO101groups, respectively (p = 0.8747 and p = 0.0745, respectively)

    PMID 40026058 · one of two readings recorded this

  • 400MWT gait speed difference vs placebo at M6, p-value (table)

    no effect, p = 0.2338

    p‐value | 0.2338 | 0.0966 | 0.6355 | 0.0492

    PMID 40026058 · one of two readings recorded this

  • 400MWT gait speed difference vs placebo at M6, p-value (table)

    no effect, p = 0.8236

    p‐value | 0.8236 | 0.2878 | 0.4706 | 0.1395

    PMID 40026058 · one of two readings recorded this

  • 400MWT gait speed difference vs placebo at M6, p-value (table)

    no effect, p = 0.7592

    p‐value | 0.7592 | 0.1415 | 0.1278 | 0.1268

    PMID 40026058 · one of two readings recorded this

  • 400MWT gait speed difference vs placebo at M6, p-value (table)

    no effect, p = 0.0966

    p‐value | 0.2338 | 0.0966 | 0.6355 | 0.0492

    PMID 40026058 · one of two readings recorded this

  • 400MWT gait speed difference vs placebo at M6, p-value (table)

    no effect, p = 0.2878

    p‐value | 0.8236 | 0.2878 | 0.4706 | 0.1395

    PMID 40026058 · one of two readings recorded this

  • 400MWT gait speed difference vs placebo at M6, p-value (table)

    no effect, p = 0.1415

    p‐value | 0.7592 | 0.1415 | 0.1278 | 0.1268

    PMID 40026058 · one of two readings recorded this

  • 400MWT gait speed LS mean CFB at M6

    LS mean CFB M6 (SE), m/s | 0.0018 (0.02903) | 0.0523 (0.03325) | 0.0680 (0.02939) | 0.0139 (0.03104) | −0.0114 (0.04451) | 0.1035 (0.03297)

    PMID 40026058 · one of two readings recorded this

  • 400MWT gait speed LS mean CFB at M6

    LS mean CFB M6 (SE), m/s | 0.0220 (0.03341) | 0.0326 (0.03626) | 0.0694 (0.03215) | 0.0279 (0.03415) | ‐0.0125 (0.04532) | 0.1024 (0.03677)

    PMID 40026058 · one of two readings recorded this

  • 400MWT gait speed LS mean CFB at M6

    LS mean CFB M6 (SE), m/s | 0.0203 (0.02677) | 0.0318 (0.02854) | 0.0724 (0.02485) | 0.0319 (0.02662) | −0.0359 (0.03601) | 0.0888 (0.02753)

    PMID 40026058 · one of two readings recorded this

  • 400MWT gait speed, LS mean difference to placebo in CFB to Month 6, new analysis with MI

    no effect, p = 0.692

    The LS mean (SE) difference to placebo in CFB to Month 6 was 0.012 (0.031) m/s and 0.069 (0.040) m/s in the 175‐ and 350‐mg BIO101 groups, respectively (p = 0.6920 and p = 0.0850, respectively)

    PMID 40026058 · one of two readings recorded this

  • 400MWT gait speed, LS mean difference to placebo in CFB to Month 6, new analysis with MI

    no effect, p = 0.085

    The LS mean (SE) difference to placebo in CFB to Month 6 was 0.012 (0.031) m/s and 0.069 (0.040) m/s in the 175‐ and 350‐mg BIO101 groups, respectively (p = 0.6920 and p = 0.0850, respectively)

    PMID 40026058 · one of two readings recorded this

  • 400MWT gait speed, LS mean difference to placebo in change from baseline, primary analysis

    no effect, p = 0.2437

    the least square (LS) mean (SE) difference to placebo in change from baseline to Month 6/9 was 0.036 (0.031) m/s and 0.039 (0.030) m/s in the 175‐and 350‐mg BIO101 groups, respectively (p = 0.2437 and p = 0.2000, respectively)

    PMID 40026058 · one of two readings recorded this

  • 400MWT gait speed, LS mean difference to placebo in change from baseline, primary analysis

    no effect, p = 0.2

    the least square (LS) mean (SE) difference to placebo in change from baseline to Month 6/9 was 0.036 (0.031) m/s and 0.039 (0.030) m/s in the 175‐and 350‐mg BIO101 groups, respectively (p = 0.2437 and p = 0.2000, respectively)

    PMID 40026058 · one of two readings recorded this

  • 400MWT gait speed LS mean difference vs placebo at M6 (table)

    LS mean difference (vs placebo)(SE) | 0.0505 (0.04209) | 0.0662 (0.03938) | −0.0254 (0.05318) | 0.0895 (0.04429)

    PMID 40026058 · one of two readings recorded this

  • 400MWT gait speed LS mean difference vs placebo at M6 (table)

    LS mean difference (vs placebo)(SE) | 0.0105 (0.04709) | 0.0474 (0.04417) | ‐0.0404 (0.05550) | 0.0745 (0.04940)

    PMID 40026058 · one of two readings recorded this

  • 400MWT gait speed LS mean difference vs placebo at M6 (table)

    LS mean difference (vs placebo) (SE) | 0.0115 (0.03722) | 0.0521 (0.03505) | −0.0678 (0.04382) | 0.0569 (0.03658)

    PMID 40026058 · one of two readings recorded this

  • 400MWT gait speed, LS mean difference vs placebo in CFB to Month 6

    no effect, p = 0.6355

    the LS mean (SE) difference compared with placebo in CFB to Month 6 was −0.025 (0.053) m/s and 0.090 (0.044) m/s in the 175‐ and 350‐mg BIO101 groups, respectively, statistically nominally significant for the latter (p = 0.6355 and p = 0.0492, respectively)

    PMID 40026058 · one of two readings recorded this

  • 400MWT gait speed, LS mean difference vs placebo in CFB to Month 6

    no effect, p = 0.4706

    the LS mean (SE) difference versus placebo in CFB to Month 6 was −0.040 (0.056) m/s and 0.075 (0.049) m/s in the 175‐ and 350‐mg BIO101 groups, respectively (p = 0.4706 and p = 0.1395, respectively)

    PMID 40026058 · one of two readings recorded this

  • 400MWT gait speed, LS mean difference vs placebo in CFB to Month 6

    no effect, p = 0.1278

    the LS mean (SE) difference versus placebo in CFB to Month 6 was −0.068 (0.044) m/s and 0.057 (0.037) m/s in the 175‐ and 350‐mg BIO101groups, respectively (p = 0.1278 and p = 0.1268, respectively)

    PMID 40026058 · one of two readings recorded this

  • 400MWT gait speed, LS mean difference vs placebo in CFB to Month 6

    increases, p = 0.0492

    the LS mean (SE) difference compared with placebo in CFB to Month 6 was −0.025 (0.053) m/s and 0.090 (0.044) m/s in the 175‐ and 350‐mg BIO101 groups, respectively, statistically nominally significant for the latter (p = 0.6355 and p = 0.0492, respectively)

    PMID 40026058 · one of two readings recorded this

  • 400MWT gait speed, LS mean difference vs placebo in CFB to Month 6

    no effect, p = 0.1395

    the LS mean (SE) difference versus placebo in CFB to Month 6 was −0.040 (0.056) m/s and 0.075 (0.049) m/s in the 175‐ and 350‐mg BIO101 groups, respectively (p = 0.4706 and p = 0.1395, respectively)

    PMID 40026058 · one of two readings recorded this

  • 400MWT gait speed, LS mean difference vs placebo in CFB to Month 6

    no effect, p = 0.1268

    the LS mean (SE) difference versus placebo in CFB to Month 6 was −0.068 (0.044) m/s and 0.057 (0.037) m/s in the 175‐ and 350‐mg BIO101groups, respectively (p = 0.1278 and p = 0.1268, respectively)

    PMID 40026058 · one of two readings recorded this

  • 400MWT gait speed, observed change from baseline at 6 months

    decreases

    with the change from baseline being −0.023 (0.128) m/s

    PMID 40026058 · one of two readings recorded this

  • 400MWT gait speed, observed difference between arm and placebo

    unclear

    The observed difference between treatment arms and placebo was 0.045 and 0.066 m/s for 175 and 350 mg BIO101, respectively, at M6/M9

    PMID 40026058 · one of two readings recorded this

  • 400MWT gait speed, observed difference between arm and placebo

    unclear

    At M6, the observed difference between treatment arms and placebo was 0.037 and 0.086 m/s for the 175‐ and 350‐mg BIO101 groups, respectively

    PMID 40026058 · one of two readings recorded this

  • 400MWT gait speed, observed difference between arm and placebo

    unclear

    0.019 and 0.078 m/s for 175 and 350 mg BIO101, respectively, at M6/M9

    PMID 40026058 · one of two readings recorded this

  • 400MWT gait speed, observed difference between arm and placebo

    unclear

    In the PP population, the observed difference between treatment arms and placebo was −0.019 and 0.102 m/s for 175 and 350 mg BIO101, respectively, at M6

    PMID 40026058 · one of two readings recorded this

  • 400MWT gait speed, observed difference between arm and placebo

    unclear

    The observed difference between treatment arms and placebo was 0.045 and 0.066 m/s for 175 and 350 mg BIO101, respectively, at M6/M9

    PMID 40026058 · one of two readings recorded this

  • 400MWT gait speed, observed difference between arm and placebo

    unclear

    At M6, the observed difference between treatment arms and placebo was 0.037 and 0.086 m/s for the 175‐ and 350‐mg BIO101 groups, respectively

    PMID 40026058 · one of two readings recorded this

  • 400MWT gait speed, observed difference between arm and placebo

    unclear

    0.019 and 0.078 m/s for 175 and 350 mg BIO101, respectively, at M6/M9

    PMID 40026058 · one of two readings recorded this

  • 400MWT gait speed, observed difference between arm and placebo

    unclear

    In the PP population, the observed difference between treatment arms and placebo was −0.019 and 0.102 m/s for 175 and 350 mg BIO101, respectively, at M6

    PMID 40026058 · one of two readings recorded this

  • 400MWT test response, adjusted odds ratio vs placebo

    no effect

    Adjusted OR (95% CI) (vs placebo) [a] | 2.57 (0.75–8.82) | 3.15 (0.95–10.43)

    PMID 40026058 · one of two readings recorded this

  • 400MWT test response, adjusted odds ratio vs placebo

    no effect

    Adjusted OR (95% CI) (vs placebo) [a] | 2.57 (0.75–8.82) | 3.15 (0.95–10.43)

    PMID 40026058 · one of two readings recorded this

  • 400MWT test response, number of responders at M6/M9

    Number of responders with M6/M9 | 4 | 9 | 11

    PMID 40026058 · one of two readings recorded this

  • 400MWT test response, p-value for adjusted OR

    no effect, p = 0.1321

    p‐value [a] | 0.1321 | 0.0603

    PMID 40026058 · one of two readings recorded this

  • 400MWT test response, p-value for adjusted OR

    no effect, p = 0.0603

    p‐value [a] | 0.1321 | 0.0603

    PMID 40026058 · one of two readings recorded this

  • 6-min walking distance, LS mean difference to placebo at Month 6/9

    no effect, p = 0.8824

    the LS mean (SE) difference to placebo at Month 6/9 in the distance walked during the 6‐min walking distance (6MWD) test was 2.714 m (18.300) and 25.607 m (17.982) in the 175‐ and 350‐mg BIO101 groups, respectively (p = 0.8824 and p = 0.1578, respectively)

    PMID 40026058 · one of two readings recorded this

  • 6-min walking distance, LS mean difference to placebo at Month 6/9

    no effect, p = 0.1578

    the LS mean (SE) difference to placebo at Month 6/9 in the distance walked during the 6‐min walking distance (6MWD) test was 2.714 m (18.300) and 25.607 m (17.982) in the 175‐ and 350‐mg BIO101 groups, respectively (p = 0.8824 and p = 0.1578, respectively)

    PMID 40026058 · one of two readings recorded this

  • 6MWD, LS mean CFB M6/9

    LS mean CFB M6/9 (SE) | −9.879 (13.6981) | −7.166 (14.7976) | 15.728 (13.4459)

    PMID 40026058 · one of two readings recorded this

  • ALM/BMI calculated, LS mean CFB M6/9

    LS mean CFB M6/9 (SE) | −0.001 (0.0101) | −0.010 (0.0112) | 0.007 (0.0097)

    PMID 40026058 · one of two readings recorded this

  • ALM/BMI calculated, LS mean difference vs placebo M6/9, p-value

    no effect, p = 0.4721

    p‐value | 0.4721 | 0.5554

    PMID 40026058 · one of two readings recorded this

  • ALM/BMI calculated, LS mean difference vs placebo M6/9, p-value

    no effect, p = 0.5554

    p‐value | 0.4721 | 0.5554

    PMID 40026058 · one of two readings recorded this

  • ALM/BMI calculated, LS mean difference vs placebo M6/9

    no effect

    LS mean difference vs Placebo (SE) | −0.009 (0.0131) | 0.008 (0.0130)

    PMID 40026058 · one of two readings recorded this

  • ALM, LS mean CFB M6/9

    LS mean CFB M6/9 (SE) | −0.276 (0.3176) | −0.283 (0.3307) | 0.068 (0.2822)

    PMID 40026058 · one of two readings recorded this

  • ALM, LS mean difference vs placebo M6/9, p-value

    no effect, p = 0.9859

    p‐value | 0.9859 | 0.4040

    PMID 40026058 · one of two readings recorded this

  • ALM, LS mean difference vs placebo M6/9, p-value

    no effect, p = 0.404

    p‐value | 0.9859 | 0.4040

    PMID 40026058 · one of two readings recorded this

  • ALM, LS mean difference vs placebo M6/9

    no effect

    LS mean difference vs placebo (SE) | −0.007 (0.3859) | 0.344 (0.4096)

    PMID 40026058 · one of two readings recorded this

  • gait speed change from baseline on the 400-m walking test (400MWT), primary endpoint

    LS mean difference to placebo 0.036 (0.031) m/s and 0.039 (0.030) m/s in the 175 and 350 mg BIO101 groups

    Not recorded as a finding: this platform holds no node for the endpoint

    In the primary analysis of 400MWT GS in the FAS, the least square (LS) mean (SE) difference to placebo in change from baseline to Month 6/9 was 0.036 (0.031) m/s and 0.039 (0.030) m/s in the 175‐and 350‐mg BIO101 groups, respectively (p = 0.2437 and p = 0.2000, respectively).

    PMID 40026058 · one of two readings recorded this

  • Handgrip strength dominant hand, LS mean CFB M6/9

    LS mean CFB M6/9 (SE) | −0.709 (1.1024) | −1.601 (1.1731) | 0.590 (1.0668)

    PMID 40026058 · one of two readings recorded this

  • Handgrip strength dominant hand, LS mean difference from placebo in CFB to Month 6/9

    no effect, p = 0.52

    the LS mean (SE) difference from placebo in CFB to Month 6/9 was −0.892 (1.381) and 1.298 (1.404) in the 175‐mg and 350‐mg BIO101 groups, respectively, which was not statistically significant (p = 0.5200 and p = 0.3577, respectively)

    PMID 40026058 · one of two readings recorded this

  • Handgrip strength dominant hand, LS mean difference from placebo in CFB to Month 6/9

    no effect, p = 0.3577

    the LS mean (SE) difference from placebo in CFB to Month 6/9 was −0.892 (1.381) and 1.298 (1.404) in the 175‐mg and 350‐mg BIO101 groups, respectively, which was not statistically significant (p = 0.5200 and p = 0.3577, respectively)

    PMID 40026058 · one of two readings recorded this

  • MMRM treatment factor significance, 400MWT gait speed CFB M6, chair stand and obesity analysis

    increases, p = 0.0037

    treatment was a significant factor in the MMRM analysis (p = 0.0037)

    PMID 40026058 · one of two readings recorded this

  • MMRM treatment factor significance, 400MWT gait speed CFB M6, low gait speed analysis

    increases, p = 0.0154

    treatment was a significant factor in the MMRM analysis (p = 0.0154)

    PMID 40026058 · one of two readings recorded this

  • PF-10 from SF-36, LS mean CFB M6/9

    LS mean CFB M6/9 (SE) | 7.3 (2.50) | 7.1 (2.64) | 7.1 (2.51)

    PMID 40026058 · one of two readings recorded this

  • PF-10 sub-score of SF-36, LS mean difference to placebo in CFB to Month 6/9

    no effect, p = 0.9408

    the LS mean (SE) difference to placebo in CFB to Month 6/9 was −0.2 (3.30) and −0.2 (3.25) in the 175‐ and 350‐mg BIO101 groups, respectively, which was not statistically significant (p = 0.9408 and p = 0.9485, respectively)

    PMID 40026058 · one of two readings recorded this

  • PF-10 sub-score of SF-36, LS mean difference to placebo in CFB to Month 6/9

    no effect, p = 0.9485

    the LS mean (SE) difference to placebo in CFB to Month 6/9 was −0.2 (3.30) and −0.2 (3.25) in the 175‐ and 350‐mg BIO101 groups, respectively, which was not statistically significant (p = 0.9408 and p = 0.9485, respectively)

    PMID 40026058 · one of two readings recorded this

  • SarQoL, LS mean CFB M6/9

    LS mean CFB M6/9 (SE) | 14.66 (2.017) | 10.81 (2.074) | 10.00 (1.979)

    PMID 40026058 · one of two readings recorded this

  • SarQoL, LS mean difference vs placebo M6/9, p-value

    no effect, p = 0.1348

    p‐value | 0.1348 | 0.0666

    PMID 40026058 · one of two readings recorded this

  • SarQoL, LS mean difference vs placebo M6/9, p-value

    no effect, p = 0.0666

    p‐value | 0.1348 | 0.0666

    PMID 40026058 · one of two readings recorded this

  • SarQoL, LS mean difference vs placebo M6/9

    no effect

    LS mean difference vs placebo (SE) | −3.85 (2.559) | −4.67 (2.521)

    PMID 40026058 · one of two readings recorded this

  • SPPB total score, LS mean CFB M6/9

    LS mean CFB M6/9 (SE) | 1.1 (0.35) | 1.0 (0.35) | 0.9 (0.33)

    PMID 40026058 · one of two readings recorded this

  • SPPB total score, LS mean difference vs placebo M6/9, p-value

    no effect, p = 0.8127

    p‐value | 0.8127 | 0.6663

    PMID 40026058 · one of two readings recorded this

  • SPPB total score, LS mean difference vs placebo M6/9, p-value

    no effect, p = 0.6663

    p‐value | 0.8127 | 0.6663

    PMID 40026058 · one of two readings recorded this

  • SPPB total score, LS mean difference vs placebo M6/9

    no effect

    LS mean difference vs placebo (SE) | −0.1 (0.47) | −0.2 (0.46)

    PMID 40026058 · one of two readings recorded this

  • abdominal fat, change

    decreases, p = 0.05

    The 20E group showed significant reductions in arm (p<0.01), leg (p<0.05), and abdominal fat (p<0.05), with arm fat reduction significantly greater than in the PLA group (p<0.05)

    PMID 41485968 · one of two readings recorded this

  • arm fat, change

    decreases, p = 0.01

    The 20E group showed significant reductions in arm (p<0.01), leg (p<0.05), and abdominal fat (p<0.05), with arm fat reduction significantly greater than in the PLA group (p<0.05)

    PMID 41485968 · one of two readings recorded this

  • arm fat reduction, 20E versus PLA

    decreases, p = 0.05

    The 20E group showed significant reductions in arm (p<0.01), leg (p<0.05), and abdominal fat (p<0.05), with arm fat reduction significantly greater than in the PLA group (p<0.05)

    PMID 41485968 · one of two readings recorded this

  • fasting insulin, change

    decreases, p = 0.01

    favorable metabolic changes, including reductions in fasting insulin (p<0.01) and plasma FFAs (p<0.05), alongside an increase in QUICKI (p<0.01)

    PMID 41485968 · one of two readings recorded this

  • fasting insulin, plasma free fatty acids and QUICKI; substrate (fat) oxidation at rest and during exercise; arm, leg and abdominal fat; abstract only, 30 mg/d 20E from Asparagus officinalis extract vs placebo, 12 wk with resistance training

    decreases, fasting insulin reduced (p<0.01), plasma FFAs reduced (p<0.05), QUICKI increased (p<0.01), reported for the 20E group without a stated between-group contrast

    Not recorded as a finding: the result compares a group with itself, not with a control

    Furthermore, 20E supplementation was associated with favorable metabolic changes, including reductions in fasting insulin (p<0.01) and plasma FFAs (p<0.05), alongside an increase in QUICKI (p<0.01).

    PMID 41485968 · one of two readings recorded this

  • fat oxidation, 20E versus PLA

    increases, p = 0.05

    Fat oxidation increased at rest and during exercise in the 20E group (p<0.01), with between-group differences evident only at 40% of V•O2peak (p<0.05)

    PMID 41485968 · one of two readings recorded this

  • fat oxidation at rest and during exercise, change

    increases, p = 0.01

    Fat oxidation increased at rest and during exercise in the 20E group (p<0.01), with between-group differences evident only at 40% of V•O2peak (p<0.05)

    PMID 41485968 · one of two readings recorded this

  • leg fat, change

    decreases, p = 0.05

    The 20E group showed significant reductions in arm (p<0.01), leg (p<0.05), and abdominal fat (p<0.05), with arm fat reduction significantly greater than in the PLA group (p<0.05)

    PMID 41485968 · one of two readings recorded this

  • plasma free fatty acids, change

    decreases, p = 0.05

    favorable metabolic changes, including reductions in fasting insulin (p<0.01) and plasma FFAs (p<0.05), alongside an increase in QUICKI (p<0.01)

    PMID 41485968 · one of two readings recorded this

  • QUICKI, change

    increases, p = 0.01

    favorable metabolic changes, including reductions in fasting insulin (p<0.01) and plasma FFAs (p<0.05), alongside an increase in QUICKI (p<0.01)

    PMID 41485968 · one of two readings recorded this

  • whole-body fat oxidation at rest and during exercise (substrate utilization); fasting insulin and plasma free fatty acids; QUICKI; regional (arm, leg, abdominal) fat. Abstract only. The 20E-group changes are within-arm, and the only between-group result stated is at 40% of VO2peak or for arm fat, which are subsets or a regional measure the nodes do not cover

    increases, fat oxidation increased at rest and during exercise in the 20E group; between-group difference only at 40% of VO2peak

    Not recorded as a finding: the result compares a group with itself, not with a control

    Fat oxidation increased at rest and during exercise in the 20E group (p<0.01), with between-group differences evident only at 40% of V•O2peak (p<0.05).

    PMID 41485968 · one of two readings recorded this